CN111249219A - 治疗耳道真菌的滴耳液及其制备方法 - Google Patents
治疗耳道真菌的滴耳液及其制备方法 Download PDFInfo
- Publication number
- CN111249219A CN111249219A CN201811460087.5A CN201811460087A CN111249219A CN 111249219 A CN111249219 A CN 111249219A CN 201811460087 A CN201811460087 A CN 201811460087A CN 111249219 A CN111249219 A CN 111249219A
- Authority
- CN
- China
- Prior art keywords
- ear
- treating
- fungus
- ear canal
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003221 ear drop Substances 0.000 title claims abstract description 51
- 235000000023 Auricularia auricula Nutrition 0.000 title claims description 15
- 241001149430 Auricularia auricula-judae Species 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title abstract description 28
- 229940047652 ear drops Drugs 0.000 title abstract description 27
- 210000000613 ear canal Anatomy 0.000 claims abstract description 47
- 241000233866 Fungi Species 0.000 claims abstract description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000003756 stirring Methods 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000008213 purified water Substances 0.000 claims abstract description 15
- 229960004130 itraconazole Drugs 0.000 claims abstract description 13
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims abstract description 12
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960004022 clotrimazole Drugs 0.000 claims abstract description 12
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims abstract description 6
- 229940043234 carbomer-940 Drugs 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- 108010014251 Muramidase Proteins 0.000 claims description 12
- 102000016943 Muramidase Human genes 0.000 claims description 12
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 12
- 239000004325 lysozyme Substances 0.000 claims description 12
- 235000010335 lysozyme Nutrition 0.000 claims description 12
- 229960000274 lysozyme Drugs 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 8
- 230000003020 moisturizing effect Effects 0.000 claims description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 108010022172 Chitinases Proteins 0.000 claims description 5
- 102000012286 Chitinases Human genes 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- 229940116229 borneol Drugs 0.000 claims description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- 108010001682 Dextranase Proteins 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 229960003639 laurocapram Drugs 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 238000005507 spraying Methods 0.000 abstract description 2
- 210000005069 ears Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 34
- 229940079593 drug Drugs 0.000 description 31
- 244000028550 Auricularia auricula Species 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 206010017533 Fungal infection Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 208000031888 Mycoses Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 208000024386 fungal infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 241000186046 Actinomyces Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000335423 Blastomyces Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229940091713 fluconazole injection Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 201000009838 otomycosis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗耳道真菌的滴耳液及其制备方法,该治疗耳道真菌的滴耳液包括以下质量分数的组分:伊曲康唑3%~20%,克霉唑2%~10%,卡波姆‑940 0.8%~2.3%,甘油5%~15%,三乙醇胺0.5%~1.5%,余量为纯化水。制备方法包括将甘油和卡波姆‑940用纯化水溶解,在搅拌中加入三乙醇胺,搅匀后得到透明凝胶,将伊曲康唑和克霉唑加入透明凝胶中搅拌,再加纯化水至整体质量分数为100%,搅拌均匀,即得。本发明的滴耳液具有抗菌效果好、治愈率高、给药方便简单、可喷涂均匀、对耳部刺激小、容易保存等优点,制备方法简单方便,成本低廉。
Description
技术领域
本发明属于药物制剂及其制备领域,涉及一种治疗耳道真菌的滴耳液及其制备方法,具体涉及一种治疗耳道真菌的伊曲康唑联合克霉唑的滴耳液及其制备方法。
背景技术
耳道真菌病,顾名思义就是不该生长于耳道内的真菌在耳道内生长繁殖而导致的一种真菌感染,主要由酵母菌、念珠菌、芽生菌、曲霉菌等病菌感染。本病一旦发作,耳朵瘙痒,可伴耳痛,有的真菌性耳道疾病患者在晚上会瘙痒得更加厉害,此时若用手反复抓挠,容易抓破外耳道皮肤而引起出血,继发感染,流脓水等。严重者甚至可引起眩晕、面瘫以及坏死性外耳道炎。
耳道真菌病患者由于脓液刺激、游泳、挖耳等因素改变了外耳道内的酸碱度和湿度,因此容易引起本病。另外,集体抵抗力低,长期口服抗生素、激素的病患以及糖尿病患者也易引起本病。并且患病率呈增加趋势,越来越多的耳道真菌感染患者到医院就诊。而其主要的致病菌有酵母菌、念珠菌、芽生菌、曲霉菌、毛霉菌、放线菌、青霉菌等。口服药物治疗并不能有效的作用于靶位置,局部给药较为合理有效。
临床上针对耳真菌病的治疗,以外用药为主,主要有以下几种方法:
(1)耳部彻底清创后,使用硼酸酒精、水杨酸酒精、复方间苯二酚溶液等抑制真菌的溶液滴耳,本法操作简单,但此类药物在使用后会产生烧灼、刺痛等反应,严重影响患者治疗依从性,难以保证治疗的彻底性,而且此类药液具有不易制备、保存不理想等缺点。
(2)使用克霉唑软膏、达克宁霜等唑类软膏这些常规药物进行涂布,具有药性温和的优势,不会产生不良反应,但其整体疗效较差,难以被患者接受,而且常因外耳道生理性弯曲及狭窄,患者很难将药物均匀地涂抹到患病的各个部位。
(3)使用抗真菌药物如氟康唑注射液耳浴治疗,药液在外耳道内持续时间长,药液浸泡整个外耳道,比上述两种方法治疗效果好,但有一定刺激性,且并不能保证稳定的临床效果。
市面上的抗真菌药物种类居多,以唑类为主且大多为口服,滴耳液制剂是治疗耳道真菌一种不错的选择,含伊曲康唑或伏立康唑等成分的滴耳制剂虽有报道,但应用并不普遍,主要原因是制剂的处方还不够成熟,安全性和有效性还有待研究证明。因此,为了解决当前治疗方式的诸多不便和治疗效果的缺陷,急需开发一种新型耳道真菌制剂。
发明内容
本发明要解决的技术问题是克服现有技术的不足,提供一种抗菌效果好、治愈率很高、给药方便简单、可喷涂均匀、对耳部刺激小、且容易保存的治疗耳道真菌的滴耳液及其制备方法。
为解决上述技术问题,本发明采用以下技术方案。
一种治疗耳道真菌的滴耳液,所述治疗耳道真菌的滴耳液包括以下质量分数的组分:
上述的治疗耳道真菌的滴耳液中,优选的,所述治疗耳道真菌的滴耳液包括以下质量分数的组分:
上述的治疗耳道真菌的滴耳液中,优选的,所述治疗耳道真菌的滴耳液还包括悬浮稳定剂、透皮剂和防腐剂中的一种或多种,按质量分数计(即组分占滴耳液的质量分数),保湿增溶剂为0.6%~1.2%,透皮剂为0.55%~1.5%,防腐剂为0.03%~0.1%。
上述的治疗耳道真菌的滴耳液中,优选的,所述防腐剂包括溶菌酶、尼泊金甲酯、尼泊金乙酯和苯甲酸中的一种或多种。
上述的治疗耳道真菌的滴耳液中,优选的,所述溶菌酶为壳多糖酶和/或葡聚糖酶。
上述的治疗耳道真菌的滴耳液中,优选的,所述保湿增溶剂包括PEG-400、丙二醇和乙醇中的一种或多种。
上述的治疗耳道真菌的滴耳液中,优选的,所述透皮剂包括冰片、月桂氮酮、薄荷醇和氮酮中的一种或多种。
作为一个总的技术构思,本发明还提供一种上述的治疗耳道真菌的滴耳液的制备方法,包括如下步骤:将甘油和卡波姆-940用纯化水溶解,然后在搅拌过程中加入三乙醇胺,搅匀后得到透明凝胶,将伊曲康唑和克霉唑加入透明凝胶中搅拌,再加纯化水至整体质量分数为100%,搅拌均匀,即得到治疗耳道真菌的滴耳液。
作为一个总的技术构思,本发明还提供一种上述的治疗耳道真菌的滴耳液的制备方法,包括如下步骤:将保湿增溶剂、卡波姆-940和甘油用纯化水溶解,然后在搅拌过程中加入三乙醇胺,搅匀后得到透明凝胶,将伊曲康唑和克霉唑加入透明凝胶中搅拌,再加入透皮剂和防腐剂,最后加纯化水至整体质量分数为100%,搅拌均匀,即得到治疗耳道真菌的滴耳液。
本发明的目的是提供一种有效控制和治疗耳道真菌病的滴耳剂及其制备方法。临床上目前专用于治疗耳道真菌病的药剂较少,而且在很多医院(甚至是三甲医院)都没有治疗耳道真菌感染的药物。临床上目前治疗耳道真菌病并没有明确的方法,药物选择较少,治疗效果并不明确,较为合理的氟康唑注射液原本也不是用于治疗耳道真菌特有药物,因此,发明提供一种有效适用的滴耳剂多剂型,可以为医生和病人提供治疗耳道真菌选择。耳道真菌感染主要的致病真菌是酵母菌、念珠菌、芽生菌、曲霉菌、毛霉菌、放线菌、青霉菌等,单一的抗真菌药物有时并不能达到最佳的治疗效果,所以本发明通过实验研究,创造性地选择了伊曲康唑与克霉唑作为复方制剂的主要成分以更好地协同治疗耳道真菌,其中,保湿增溶剂(如PEG-400,即聚乙二醇400)促进可药物的溶解,甘油为粘稠剂,促进药物的透皮吸收,三乙醇胺为乳化剂和pH调节剂,纯化水为溶剂,促进各成分的溶解混合和协同增效。
特别地,本发明首次提出溶菌酶可以作为滴耳液中的天然药品防腐材料,替代了常规的防腐剂,溶菌酶可采用壳多糖酶和/或葡聚糖酶,这一技术手段是现有技术中从未提出过的,采用溶菌酶作为防腐剂,相比于现有的防腐剂,溶菌酶降低了对机体刺激,减少了化学防腐剂带来的不良反应,溶菌酶更天然而且具有较好的抑菌效果,可以与药物主成分协同抵抗耳道真菌,极大地增加了滴耳剂的治疗效果,提高了治愈率。
与现有技术相比,本发明的优点在于:
1、本发明以广谱抗真菌药物-伊曲康唑和克霉唑为主要药物成分制成临床制剂,伊曲康唑(Itraconazole)为人工合成的三氮唑衍生物,是一种合成的广谱抗真菌药,通过改变真菌细胞膜通透性发挥抗菌活性,对浅部、深部真菌感染的病原菌均有抗菌活性,其抗菌谱广泛。克霉唑是咪唑类衍生物,是一种广谱抗真菌药,能破坏真菌细胞膜使细胞内容物外漏而杀灭真菌,其价格低廉,被广泛用于真菌性皮肤病感染中,且主要用于局部。本发明的滴耳液可以起到有效的抑制多类型耳道真菌的繁殖、生长的作用。
现有技术大多选用乙醇作为溶剂来提高药物的渗透性和杀菌作用,但乙醇的刺激性较强,尤其耳内部皮肤敏感,更易造成患者的不适,严重影响患者的依从性。而本发明选用甘油作为溶剂,溶剂作用缓和、药效持久,为了加强药物的吸收,可优选透皮吸收较强且对皮肤刺激性较小的氮酮作为透皮吸收剂,协同增强了药物快速进入体内。目前滴耳制剂都为单一药物制剂,而本发明为两种唑类药物的复合制剂,通过加入保湿增溶剂、甘油来增加疏水药物在溶剂中的溶解度,三乙醇胺作为一种安全高效的乳化剂促进凝胶的形成,最后加入纯化水充分混匀溶解药物,形成比较稳定的药物制剂(粘度可稍大于纯液体),最后通过添加天然无害的防腐剂来延长药物的使用期限,保证药物的疗效稳定。特别注意的是,本发明选用的溶菌酶(可商购)是现有采用生物工程技术进行克隆、提取而制取的,它是一种天然酶,安全绿色的添加剂,无抗药性。本产品辅料中可使用溶菌酶代替常规使用的化学防腐剂,除了能增加药物的保质期并对人体无害之外,还有就是溶菌酶对真菌有抑制作用,与药物起了协同抑制真菌繁殖生长的作用,这是现有技术中从未被提出过的。
2、本发明的治疗耳道真菌的滴耳液无刺激性、治疗效果显著、成本较低,大大增加外耳道真菌感染的治愈率,同时使用方便,价格低廉,配制简单,质量可控。
3、本发明的制备方法简单方便,成本低廉。
具体实施方式
以下结合具体优选的实施例对本发明作进一步描述,但并不因此而限制本发明的保护范围。
以下实施例中所采用的材料和仪器均为市售。
实施例1:
一种本发明的治疗耳道真菌的滴耳液,由以下质量分数的组分组成:
一种上述本实施例的治疗耳道真菌的滴耳液的制备方法,包括以下步骤:
取卡波姆-940、PEG-400、甘油和能溶解掉这三种物质的适量纯化水混合搅拌,在搅拌中加入三乙醇胺,搅匀后即得透明凝胶。将伊曲康唑和克霉唑加入凝胶中搅拌,再加入氮酮、壳多糖酶和葡聚糖酶,最后加纯化水至总质量为100g,搅拌均匀,即得到治疗耳道真菌的滴耳液。
上述本实施例制备的滴耳液可采用现有的适合滴耳液的瓶装容器进行装载,优选该瓶装容器具有可伸入耳道的塑料软管,滴管头采用硅胶,避免损伤耳组织。通过瓶装容器喷入外耳道,用于外耳道给药治疗。
实施例2:
一种本发明的治疗耳道真菌的滴耳液,由以下质量分数的组分组成:
本实施例的制备方法同实施例1。
实施例3:
一种本发明的治疗耳道真菌的滴耳液,由以下质量分数的组分组成:
本实施例的制备方法同实施例1。
实施例4:
为了比较天然防腐剂与化学防腐剂的治疗效果,将实施例3的壳多糖酶和葡聚糖酶换为尼泊金甲酯。
一种本发明的治疗耳道真菌的滴耳液,由以下质量分数的组分组成:
本实施例的制备方法同实施例1。
体外试验:
本发明的抗耳道真菌喷雾剂药理、毒理学实验研究。
(1)体外抑菌实验:体外抑菌试验采用牛津杯法,并与无菌纯水(空白对照)进行对比。具体操作步骤如下:将保存的霉菌、酵母菌、念珠菌活化后分别制成菌悬液,菌悬液浓度调整至106CFU/mL,采用涂布法制备抑菌平板,涂布均匀,菌液不可过多,以平板上无液体流淌为宜,制成后用牛津杯抑菌圈法比较各实施例处方制剂的抑菌效果。即先将灭菌牛津杯在酒精灯火焰上迅速过火后,垂直放置在抑菌平板培养基表面,轻轻按压至杯底与培养基间无缝隙。每个平板放置5个牛津杯(包括4个实施例处方及无菌纯水对照),每个牛津杯中注入200微升药液或无菌纯水。每种抑菌平板做3次重复,37℃培养24h,观察,测量并记录。参照美国临床和实验室标准协会抗菌药物体外药敏判断标准:抑菌环直径﹥20mm为高度敏感,抑菌环直径10~20mm为中度敏感,抑菌环直径<10mm为耐药或无效。因此,由表1可知,本发明中4个实施例处方制剂均有强力的抗曲霉菌、酵母菌、念珠菌效果,药敏为高度敏感。
表1各实施例与无菌纯水体外抑菌试验抑菌圈均值单位:毫米(mm)
注:每组实验重复3次。
(2)毒理学实验:急性毒性试验,将实验用小鼠随机分为两组,即高剂量组和低剂量组,分别灌胃。低剂量组按该药透皮吸收量的10倍灌胃,高剂量组按该药透皮吸收量的500倍灌胃。结果灌胃后小鼠无一例死亡,说明该药无毒,作为滴耳液使用是一种安全的药物。试验结果见下表2。
表2各实施例急性毒性实验
(3)皮肤刺激试验:将白色家兔于给药前24小时背部两侧去毛,但不损伤皮肤。实验时取本品滴耳液2ml及生理盐水2ml分别滴于消毒滤纸,贴于家兔左侧和右侧背部,用一层油纸及两层纱布覆盖,用胶布封闭,分别于30分钟、60分钟、24小时及48小时检查该药对家兔皮肤刺激反应。结果家兔皮肤均无红斑及水肿,说明该药对皮肤无刺激。试验结果见表3。
注:“-”表示症状阴性,无红斑与水肿。
实施例3与实施例4,两者制备方法一样,各含量成分一致,唯一不同的是防腐剂的选择不同,通过体外实验我们可以观察到,实施例4的抑菌效果和皮肤刺激实验的效果并没有实施案例3好,毒理学实验两者一致。我们可以得出:本产品选用天然防腐剂溶菌酶时的抑菌效果强于普通化学防腐剂,且安全有效。
以上所述,仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制。虽然本发明已以较佳实施例揭示如上,然而并非用以限定本发明。任何熟悉本领域的技术人员,在不脱离本发明的精神实质和技术方案的情况下,都可利用上述揭示的方法和技术内容对本发明技术方案做出许多可能的变动和修饰,或修改为等同变化的等效实施例。因此,凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所做的任何简单修改、等同替换、等效变化及修饰,均仍属于本发明技术方案保护的范围内。
Claims (9)
3.根据权利要求1或2所述的治疗耳道真菌的滴耳液,其特征在于,所述治疗耳道真菌的滴耳液还包括保湿增溶剂、透皮剂和防腐剂中的一种或多种,按质量分数计,保湿增溶剂为0.6%~1.2%,透皮剂为0.55%~1.5%,防腐剂为0.03%~0.1%。
4.根据权利要求3所述的治疗耳道真菌的滴耳液,其特征在于,所述防腐剂包括溶菌酶、尼泊金甲酯、尼泊金乙酯和苯甲酸中的一种或多种。
5.根据权利要求4所述的治疗耳道真菌的滴耳液,其特征在于,所述溶菌酶为壳多糖酶和/或葡聚糖酶。
6.根据权利要求3所述的治疗耳道真菌的滴耳液,其特征在于,所述保湿增溶剂包括PEG-400、丙二醇和乙醇中的一种或多种。
7.根据权利要求3所述的治疗耳道真菌的滴耳液,其特征在于,所述透皮剂包括冰片、月桂氮酮、薄荷醇和氮酮中的一种或多种。
8.一种如权利要求1或2所述的治疗耳道真菌的滴耳液的制备方法,其特征在于,包括如下步骤:将甘油和卡波姆-940用纯化水溶解,然后在搅拌过程中加入三乙醇胺,搅匀后得到透明凝胶,将伊曲康唑和克霉唑加入透明凝胶中搅拌,再加纯化水至整体质量分数为100%,搅拌均匀,即得到治疗耳道真菌的滴耳液。
9.一种如权利要求3~7中任一项所述的治疗耳道真菌的滴耳液的制备方法,其特征在于,包括如下步骤:将保湿增溶剂、卡波姆-940和甘油用纯化水溶解,然后在搅拌过程中加入三乙醇胺,搅匀后得到透明凝胶,将伊曲康唑和克霉唑加入透明凝胶中搅拌,再加入透皮剂和防腐剂,最后加纯化水至整体质量分数为100%,搅拌均匀,即得到治疗耳道真菌的滴耳液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811460087.5A CN111249219B (zh) | 2018-11-30 | 2018-11-30 | 治疗耳道真菌的滴耳液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811460087.5A CN111249219B (zh) | 2018-11-30 | 2018-11-30 | 治疗耳道真菌的滴耳液及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111249219A true CN111249219A (zh) | 2020-06-09 |
| CN111249219B CN111249219B (zh) | 2023-08-11 |
Family
ID=70942823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811460087.5A Active CN111249219B (zh) | 2018-11-30 | 2018-11-30 | 治疗耳道真菌的滴耳液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111249219B (zh) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020261A2 (en) * | 1997-10-22 | 1999-04-29 | Jens Ponikau | Use of antigunal agents for the topial treatment of fungus-induced mucositis |
| CN1372974A (zh) * | 2001-03-02 | 2002-10-09 | 凌沛学 | 一种以溶菌酶为主要成分的外用凝胶剂及其制备方法 |
| CN1380060A (zh) * | 2002-04-28 | 2002-11-20 | 中国人民解放军第二军医大学 | 外用抗真菌药物的溶液型喷雾剂及其制备方法 |
| US20050043251A1 (en) * | 2003-08-20 | 2005-02-24 | Fairfield Clinical Trials, Llc | Method of treatment of otitis externa |
| RU2004111595A (ru) * | 2001-10-16 | 2005-04-10 | МакНЕЙЛ-ППС, ИНК. (US) | Новые способы лечения местных грибковых и бактериальных инфекций |
| US20070054844A1 (en) * | 2003-08-20 | 2007-03-08 | Fairfield Clinical Trials, Llc | Method for treating otitis externa |
| CN102505180A (zh) * | 2011-09-16 | 2012-06-20 | 彭可扬 | 一种用于防治室内微生物污染的负载伊曲康唑-溶菌酶电纺纤维膜 |
| CN102526132A (zh) * | 2012-02-13 | 2012-07-04 | 曹汉海 | 一种抗真菌滴耳液及其制备方法 |
| CN103182074A (zh) * | 2011-12-30 | 2013-07-03 | 沈阳兴齐眼药股份有限公司 | 一种含有溶菌酶的眼用制剂 |
| CN107854427A (zh) * | 2017-11-09 | 2018-03-30 | 广州博济医药生物技术股份有限公司 | 一种氟康唑滴耳液及其制备方法 |
-
2018
- 2018-11-30 CN CN201811460087.5A patent/CN111249219B/zh active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020261A2 (en) * | 1997-10-22 | 1999-04-29 | Jens Ponikau | Use of antigunal agents for the topial treatment of fungus-induced mucositis |
| CN1372974A (zh) * | 2001-03-02 | 2002-10-09 | 凌沛学 | 一种以溶菌酶为主要成分的外用凝胶剂及其制备方法 |
| RU2004111595A (ru) * | 2001-10-16 | 2005-04-10 | МакНЕЙЛ-ППС, ИНК. (US) | Новые способы лечения местных грибковых и бактериальных инфекций |
| CN1380060A (zh) * | 2002-04-28 | 2002-11-20 | 中国人民解放军第二军医大学 | 外用抗真菌药物的溶液型喷雾剂及其制备方法 |
| US20050043251A1 (en) * | 2003-08-20 | 2005-02-24 | Fairfield Clinical Trials, Llc | Method of treatment of otitis externa |
| US20070054844A1 (en) * | 2003-08-20 | 2007-03-08 | Fairfield Clinical Trials, Llc | Method for treating otitis externa |
| CN102505180A (zh) * | 2011-09-16 | 2012-06-20 | 彭可扬 | 一种用于防治室内微生物污染的负载伊曲康唑-溶菌酶电纺纤维膜 |
| CN103182074A (zh) * | 2011-12-30 | 2013-07-03 | 沈阳兴齐眼药股份有限公司 | 一种含有溶菌酶的眼用制剂 |
| CN102526132A (zh) * | 2012-02-13 | 2012-07-04 | 曹汉海 | 一种抗真菌滴耳液及其制备方法 |
| CN107854427A (zh) * | 2017-11-09 | 2018-03-30 | 广州博济医药生物技术股份有限公司 | 一种氟康唑滴耳液及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| ZHAO, X ET AL.: "Profiling and Preparation of Metabolites from Pyragrel in Human Urine by Online Solid-Phase Extraction Coupled with High Performance Liquid Chromatography Tandem Mass Spectrometry Followed by a Macroporous Resin-Based Purification Approach", MOLECULES, vol. 22, pages 1 - 13 * |
| 黄洁: "空腹或餐后服用国产伊曲康唑胶囊的人体生物等效性研究", 临床药理学, vol. 18, pages 527 - 531 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111249219B (zh) | 2023-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6572849B2 (en) | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications | |
| US8968794B2 (en) | Antiseptic compositions and uses thereof | |
| US9808491B2 (en) | Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof | |
| JPH054918A (ja) | 安定な水性製剤 | |
| US20220354953A1 (en) | Photodynamic therapy compositions and methods of treatment therein | |
| US20050080043A1 (en) | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications | |
| JP2023541257A (ja) | 光線力学療法組成物及びその使用方法 | |
| CN103006561A (zh) | 一种脂质体纳米银凝胶及其制备方法 | |
| NO333349B1 (no) | Avleveringssystem for innforing i den ytre oregangen som omfatter en flyktig substans for a behandle eller forebygge mellomorebetennelse. | |
| CN111249233A (zh) | 抗耳道真菌喷雾剂及其制备方法和喷雾装置 | |
| CN102600195A (zh) | 一种宠物用复方透皮搽剂及其制备方法和应用 | |
| CN112263544B (zh) | 一种盐酸利多卡因凝胶及其制备方法 | |
| CN110974861B (zh) | 一种艾纳香油脂质体 | |
| CN111249219B (zh) | 治疗耳道真菌的滴耳液及其制备方法 | |
| CN110193017B (zh) | 一种促毛发生长的喷膜剂及其制备方法 | |
| CN106580927A (zh) | 一种环吡酮胺喷膜剂及其制备方法 | |
| CN1985883B (zh) | 一种抗真菌药物组合物及其制备方法与用途 | |
| CN111973622B (zh) | 一种氧氟沙星眼部外用组合物 | |
| CN106924279B (zh) | 蒺藜tts-12的应用、抑制须癣毛癣菌的中药凝胶剂及其制备方法 | |
| CN101163486B (zh) | 阿奇霉素在生产用于治疗眼部感染的药物中的用途 | |
| CN112535690A (zh) | 供氧与杀菌二合一的三氧眼部清洗护理洗剂 | |
| CN116159018B (zh) | 一种新型外用溴莫尼定凝胶剂 | |
| EA002267B1 (ru) | Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат | |
| CN112972516B (zh) | 一种用于外耳道炎的消毒产品 | |
| CN113082029B (zh) | 一种伤口清洗消毒剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |